Infectious bronchitis virus vaccine
Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.
1. An infectious bronchitis vaccine for use in immunizing an avian comprising an immunogenically effective amount of the Georgia 98 (GA-98) attenuated strain deposited at the American Tissue Culture Collection under accession no. PTA-4820, and a pharmaceutically acceptable carder or diluent.
2. The vaccine of claim 1 wherein the strain is inactivated.
3. A method for protecting avians against infectious bronchitis virus, comprising administering a vaccine according to claim 1 to susceptible birds.
4. An infectious bronchitis vaccine according to claim 1 , comprising additional avian vaccine immunogens.
5. An inactivated infectious bronchitis vaccine according to claim 2 , comprising additional inactivated avian vaccine immunogens.
6. The method of claim 3 wherein the avian is poultry.
7. The method of claim 6 wherein the vaccine is administered via one of eye drop, nose drop, in drinking water, or by spraying the birds.
8. The method of claim 6 wherein the vaccine is administered within a range of log 10 3.0 to log 10 7.0 EID 50 per bird.
9. A method of producing a vaccine comprising the Georgia 98 (GA-98) attenuated strain deposited at the American Tissue Culture Collection under accession no. PTA-4820 comprising the steps of:
inoculating a suitable substrate with the GA-98 virus strain;
growing the strain on the substrate;
harvesting the virus; and
formulating a vaccine from the virus.
10. The method of claim 9 wherein the substrate is a substrate selected from a specific pathogen free egg (SPF egg), a mammalian cell, and an avian cell.
11. The method of claim 9 wherein the step of formulating the vaccine further comprises mixing the virus with a pharmaceutically acceptable carder or diluent.
12. The method of claim 9 further comprising heat treating the virus.
13. The method of claim 9 further comprising the step of lyophilizing or freezing the vaccine.
14. The method of claim 13 further comprising rehydrating the vaccine.